
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is poised for strong growth in the coming years, with a diversified portfolio of diagnostic and radiotherapeutic products that are addressing unmet needs in both cardiology and oncology. The recent 1Q26 earnings beat demonstrates continued momentum in key products such as Pylarify, DEFINITY, and Neuraceq, while management's conservative approach to guidance and plans to find a successor for the CEO role instills further confidence in the company's future performance. With a strategic focus on expanding its market presence and partnerships, Lantheus Holdings is well-positioned to continue delivering strong revenue and EPS growth in the years ahead.
Bears say
Lantheus Holdings is facing significant challenges as a radiopharmaceutical-focused company, with a lack of contribution from new therapeutic and diagnostic opportunities and a projected flat gross profit for the next year. With a relatively low multiple of 20x, it may be perceived as inexpensive compared to similar-sized, high-growth peers, but its performance and future outlook appear to be lagging behind the industry. The increase in price target to $115 is based on a better visibility to a potential acceleration in 2027, but with the stock currently trading at 17.5x P/E, it may still struggle to close the gap with its peers.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares